Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | ALDH3A1 | P30838 | 8/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.39 |
| ▸ | ALDH2 | P05091 | 4/20 | 0.39 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | GNRHR | P30968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2304043 | 0.81 | CHRM5 (0.58) | CHRM5ALDH1A1ALDH3A1CHRM3CHRM1 | |
| SCHEMBL4850993 | 0.80 | SCN9A (0.41) | CHRM5SCN9ASCN7ASCN5ASCN2A | |
| SCHEMBL281593 | 0.78 | CHRM5 (0.60) | CHRM5ALDH1A1ALDH3A1 | |
| SCHEMBL12930211 | 0.73 | CHRM5 (0.76) | CHRM5ALDH1A1ALDH3A1CHRM3CHRM1 | |
| SCHEMBL3329555 | 0.72 | SCN9A (0.46) | CHRM5ALDH1A1ALDH3A1SCN9AALDH2 | |
| SCHEMBL3606824 | 0.72 | SCN9A (0.40) | CHRM5ALDH1A1ALDH3A1CHRM3CHRM1 | |
| SCHEMBL3593665 | 0.72 | SCN9A (0.40) | CHRM5CHRM3CHRM1SCN9ASCN7A | |
| SCHEMBL5001267 | 0.70 | CHRM5 (0.60) | CHRM5ALDH1A1ALDH3A1CHRM1 | |
| SCHEMBL5001336 | 0.69 | CHRM5 (0.58) | CHRM5ALDH1A1ALDH3A1CHRM1 | |
| SCHEMBL282029 | 0.69 | SCN9A (0.47) | CHRM5ALDH1A1SCN9ASCN7ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3241834-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2017-11-08 | — | — | EP | disclosed |
| EP-2428515-B9 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2014-09-17 | — | — | EP | disclosed |
| EP-2752417-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2014-07-09 | — | — | EP | disclosed |
| EP-2428515-B1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2014-05-07 | — | — | EP | disclosed |
| US-8466188-B2 | Use of spiro-oxindole compounds as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-06-18 | — | — | US | disclosed |
| US-20120122909-A9 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| EP-2428515-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2012-03-14 | — | — | EP | disclosed |
| EP-2073806-B1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-15 | — | — | EP | disclosed |
| EP-1888595-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-01 | — | — | EP | disclosed |
| US-8106087-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-7935721-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2011-05-03 | — | — | US | disclosed |
| US-20100173967-A1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-07-08 | — | — | US | disclosed |
| US-20100130487-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-05-27 | — | — | US | disclosed |
| US-20100125072-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-05-20 | — | — | US | disclosed |
| US-7700641-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| WO-2008046083-A2 | USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| EP-1877378-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-01-16 | — | — | EP | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
| WO-2006113864-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | CHRM5 355/4885ALDH1A1 1136/4885ALDH3A1 1159/4885 |
| US-20100125072-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | CHRM5 667/4885ALDH1A1 838/4885ALDH3A1 304/4885 |
| US-20100130487-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | CHRM5 667/4885ALDH1A1 838/4885ALDH3A1 304/4885 |
| US-20120122909-A9 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | CHRM5 667/4885ALDH1A1 838/4885ALDH3A1 304/4885 |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | OPRK1, OPRD1, SCN3A | CHRM5 667/4885ALDH1A1 838/4885ALDH3A1 304/4885 |
| US-20100173967-A1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | KLK3, REN, AVPR1B | CHRM5 516/4885ALDH1A1 1202/4885ALDH3A1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.